A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes
Status:
Completed
Trial end date:
2014-01-28
Target enrollment:
Participant gender:
Summary
This trial is conducted in Japan. The aim of the trial is to evaluate the pharmacokinetic
(the exposure of the trial drug in the body) and pharmacodynamic (the effect of the trial
drug on the body) properties of FIAsp (faster-acting insulin aspart) and the currently
marketed insulin aspart (NovoRapid®) in Japanese subjects with type 1 diabetes.